The African debate
How can Africa build its pharmaceutical sovereignty?
Inauguration of the generic drug manufacturing plant, Cinpharm, in Douala, Cameroon in April 2010. (Ph. Nadel)
By: Alain Foka Follow
1 min
In 2020, the Covid-19 crisis has highlighted Africa's heavy dependence on the supply of pharmaceutical products.
How to structure an industrial drug and vaccine sector and move from consumer to producer?
And African research in all this, where is it?
How can the African Medicines Agency and governments support scientists and industrialists?
When will Africa be able to treat Africans?
Advertising
With the participation of :
Dr Oumy Ndao
, Director General of the Senegalese Pharmaceutical Regulatory Agency
Michel Sidibé
, African Union Special Envoy for the African Medicines Agency (AMA), former Minister of Health and Social Affairs of the Republic of Mali and former Executive Director of UNAIDS
Pr Halidou Tinto
, Director of Research in Parasitology and associate teacher at the Nazi Boni University of Bobo-Dioulasso, regional director of the Institute for Research in Health Sciences (IRSS), principal investigator of the vaccine trial project on R21 malaria vaccine candidate.
Newsletter
Receive all the international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_EN
Health and medicine
On the same subject
The Sanofi laboratory is committed to producing 30 drugs at cost price for disadvantaged countries
Africa economy
In South Africa, the awakening of the pharmaceutical industry
Gabon: drugs now produced locally